In patients with myasthenia gravis who are being initiated on eculizumab therapy because their disease is refractory to standard treatments, the safety of an abbreviated washout period in ...
If you have an immunodeficiency related to certain infections, inflammatory diseases, or autoimmune disorders, you may have heard about an infusion treatment called intravenous immunoglobulin, or IVIG ...
BACKGROUND: Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary ...
IVIG has been used to treat AIN, but it is not always effective. We report a patient in which the concommitant use of IVIG and steroid was more effective than either alone. A 10 year old girl with ...
Immunoglobulins are proteins the body produces to protect itself. Each infusion lasts about five hours and is done two days per week, every three to four weeks. Patients may feel fatigued or have ...
Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...
This was a single-arm, interventional-, single-center, open-label prospective study. Patients with a history of probable MSA [15] were enrolled in the study (Table 1). All patients had some ...
Preterm newborns are susceptible of invasion by microorganisms due to immaturity of their immune system. This study aimed at assessing the effect of IV immunoglobulins as supportive treatment in ...
Some IVIG brands, like Gammagard, contain added sugar. This could cause your blood glucose to rise temporarily. But studies don’t show weight gain as a typical side effect of IVIG. Intravenous ...
TEANECK, N.J., July 16, 2025 /PRNewswire/ -- GC Biopharma USA, Inc., a leader in plasma-derived products, announced the presentation of new data on the viscosity of several commercially available 10% ...
The FDA approved intravenous immunoglobulins (IVIG; Octagam 10%) for treating adults with dermatomyositis, a rare chronic autoimmune disease, drugmaker Octapharma announced on Tuesday. Support for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback